Pharmacoeconomic review report : Riociguat (Adempas)

Pharmacoeconomic review report Riociguat (Adempas)

Riociguat (Adempas) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1), as monotherapy or in combination with endothelin receptor antagonists (ERAs) in adult patients (≥ 18 years of age) with W...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: [Ottawa, Ontario] : Canadian Agency for Drugs and Technologies in Health 2015.
Colección:Common drug review clinical review report.
Materias:
Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268306719
Tabla de Contenidos:
  • Expand AllCollapse All
  • Abbreviations
  • Summary
  • Background
  • Summary of the economic analysis submitted by the manufacturer
  • Key limitations
  • Issues for consideration
  • Results and conclusions
  • APPENDIX 1. Cost Comparison
  • APPENDIX 2. Price Reduction Analysis
  • APPENDIX 3. Reviewer Worksheets
  • APPENDIX 4. Treatment Pathway Diagrams
  • References.

Ejemplares similares